INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) PRODUCES A DOSE-PROPORTIONAL GLUCOSE-LOWERING EFFECT IN SUBJECTS WITH TYPE 1 DIABETES

被引：0
|
作者：
Heise, T. [1 ]
Nosek, L. [1 ]
Coester, H. [1 ]
Klein, O. [1 ]
Roepstorff, C. [2 ]
Svendsen, A. L. [2 ]
Haahr, H. [2 ]
机构：
[1] Profil Inst Stoffwechselforsch, Neuss, Germany
[2] Novo Nordisk AS, Soborg, Denmark
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2014年 / 106卷
关键词：
D O I：
10.1016/S0168-8227(14)70536-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO242
引用
收藏
页码：S173 / S174
页数：2
相关论文
共 50 条
  • [31] Higher Early Insulin Exposure and Greater Early Glucose-Lowering Effect with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Mellitus (T1DM)
    Haahr, Hanne
    Hoevelmann, Ulrike
    Brondsted, Lise
    Adrian, Charlotte L.
    Nosek, Leszek
    Heise, Tim
    [J]. DIABETES, 2014, 63 : A233 - A233
  • [32] Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
    Thalange, Nandu
    Deeb, Larry
    Iotova, Violeta
    Kawamura, Tomoyuki
    Klingensmith, Georgeanna
    Philotheou, Areti
    Silverstein, Janet
    Tumini, Stefano
    Ocampo Francisco, Ann-Marie
    Kinduryte, Ona
    Danne, Thomas
    [J]. PEDIATRIC DIABETES, 2015, 16 (03) : 164 - 176
  • [33] Insulin Degludec/Insulin Aspart (IDegAsp) Twice Daily (BID) vs. Biphasic Insulin Aspart 30 (BIAsp 30) BID-A Randomized Trial in Chinese Patients with Type 2 Diabetes
    Yang, Wenying
    Ma, Jianhua
    Hong, Tianpei
    Liu, Ming
    Miao, Heng
    Peng, Yongde
    Wang, Changjiang
    Xu, Xiangjin
    Yang, Tao
    Nielsen, Anne Moeller
    Pan, Lili
    Liu, Weihong
    Zhao Weigang
    [J]. DIABETES, 2018, 67
  • [34] Efficacy of Insulin Degludec/Insulin Aspart (IDegAsp) vs. Insulin Glargine (IGlarU300) in Insulin-Naïve Patients with Type 2 Diabetes: A Retrospective Study
    Hasnani, Dhruvi
    Jha, Santosh
    Saboo, Banshi
    Prasanna, Pusala Lakshmi
    Sanghvi, Ami
    Sowani, Alpana
    Chavda, Vipul
    [J]. CLINICAL DIABETOLOGY, 2024, 13 (01): : 67 - 75
  • [35] Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect
    Nosek, L.
    Heise, T.
    Bottcher, S. G.
    Hastrup, H.
    Haahr, H.
    [J]. DIABETOLOGIA, 2011, 54 : S429 - S429
  • [36] Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
    Luo, Qiong
    Zhou, Li
    Zhou, Naitong
    Hu, Ming
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [37] A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
    Mathieu, C.
    Rodbard, H. W.
    Cariou, B.
    Handelsman, Y.
    Philis-Tsimikas, A.
    Francisco, A. M. Ocampo
    Rana, A.
    Zinman, B.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (07): : 636 - 644
  • [38] Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
    Ahren, Bo
    [J]. WORLD JOURNAL OF DIABETES, 2014, 5 (01): : 40 - 51
  • [39] Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes
    Biester, Torben
    Danne, Thomas
    Blaesig, Sarah
    Remus, Kerstin
    Aschemeier, Baerbel
    Kordonouri, Olga
    Bardtrum, Lars
    Haahr, Hanne
    [J]. PEDIATRIC DIABETES, 2016, 17 (08) : 642 - 649
  • [40] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN
    Saiyarsarai, P.
    Khosroshahi, Ghazizadeh A.
    Khedmati, J.
    Ghaffari, S.
    Soleymani, F.
    Seyyedifar, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S576 - S576
12345